Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD

Showa Inan General Hospital

Status: Enrolling

Conditions: LRG Levels

Treatments: Diagnostic Test: serum leucine-rich alpha-2 glycoprotein (LRG) levels

Study type: Observational

Funder types: Other

Identifiers

NCT04535882

LRG

Details and patient eligibility

About

We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.

Full description

Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy with histology were performed within 7 days.The disease activity of UC and CD patients was evaluated by the Mayo score and Crohn disease activity index (CDAI), respectively. The Mayo endoscopy score was evaluated. UC patients whose Mayo endoscopy score was 2 or 3 were divided into the active UC group.

CD patients whose CDAI >150 were divided into the active CD group.

Enrollment: 125 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients whom possible UC or Crohn disease was suspected

Exclusion criteria

• other autoimmune diseases
• acute or chronic renal failure
• chronic heart diseases
• liver cirrhosis
• cancer
• acute or chronic infections
• ischemic colitis
• infectious colitis